CN115583919A - 一种6-氧烷基1,2,4-三嗪-3,5(2h,4h)-二酮类衍生物的制备方法 - Google Patents
一种6-氧烷基1,2,4-三嗪-3,5(2h,4h)-二酮类衍生物的制备方法 Download PDFInfo
- Publication number
- CN115583919A CN115583919A CN202210493704.1A CN202210493704A CN115583919A CN 115583919 A CN115583919 A CN 115583919A CN 202210493704 A CN202210493704 A CN 202210493704A CN 115583919 A CN115583919 A CN 115583919A
- Authority
- CN
- China
- Prior art keywords
- triazine
- dione
- bis
- tert
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 117
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000007800 oxidant agent Substances 0.000 claims abstract description 15
- 230000001590 oxidative effect Effects 0.000 claims abstract description 15
- 239000011941 photocatalyst Substances 0.000 claims abstract description 10
- 239000001301 oxygen Substances 0.000 claims abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 111
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 106
- -1 ether compound Chemical class 0.000 claims description 54
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 53
- 239000000463 material Substances 0.000 claims description 36
- YTPSFXZMJKMUJE-UHFFFAOYSA-N 2-tert-butylanthracene-9,10-dione Chemical compound C1=CC=C2C(=O)C3=CC(C(C)(C)C)=CC=C3C(=O)C2=C1 YTPSFXZMJKMUJE-UHFFFAOYSA-N 0.000 claims description 34
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical group [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 34
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 34
- 238000004440 column chromatography Methods 0.000 claims description 34
- 230000005855 radiation Effects 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- OUKPSCDFKNISOV-UHFFFAOYSA-N 2,4-dibenzyl-1,2,4-triazine-3,5-dione Chemical compound O=C1N(CC=2C=CC=CC=2)C(=O)C=NN1CC1=CC=CC=C1 OUKPSCDFKNISOV-UHFFFAOYSA-N 0.000 claims description 11
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 claims description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 6
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical group CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 5
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 5
- XEMKAWDHPYXCKU-UHFFFAOYSA-N 4-methyl-2h-1,2,4-triazine-3,5-dione Chemical compound CN1C(=O)C=NNC1=O XEMKAWDHPYXCKU-UHFFFAOYSA-N 0.000 claims description 5
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical class O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 claims description 5
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 5
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims description 5
- 125000005429 oxyalkyl group Chemical group 0.000 claims description 5
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 claims description 4
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- IVHDZUFNZLETBM-IWSIBTJSSA-N acridine red 3B Chemical compound [Cl-].C1=C\C(=[NH+]/C)C=C2OC3=CC(NC)=CC=C3C=C21 IVHDZUFNZLETBM-IWSIBTJSSA-N 0.000 claims description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- ZBQZBWKNGDEDOA-UHFFFAOYSA-N eosin B Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC([N+]([O-])=O)=C(O)C(Br)=C1OC1=C2C=C([N+]([O-])=O)C(O)=C1Br ZBQZBWKNGDEDOA-UHFFFAOYSA-N 0.000 claims description 4
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 4
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 claims description 4
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 4
- 229940043267 rhodamine b Drugs 0.000 claims description 4
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 claims description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- IVFPHZYXZYQYNI-UHFFFAOYSA-N 2,4-dimethyl-1,2,4-triazine-3,5-dione Chemical compound CN1N=CC(=O)N(C)C1=O IVFPHZYXZYQYNI-UHFFFAOYSA-N 0.000 claims description 3
- ODZYNEQCDJBCAX-UHFFFAOYSA-N 2-benzyl-1,2,4-triazine-3,5-dione Chemical compound O=C1NC(=O)C=NN1CC1=CC=CC=C1 ODZYNEQCDJBCAX-UHFFFAOYSA-N 0.000 claims description 3
- XGPCOQNUQVZURR-UHFFFAOYSA-N 2-phenyl-1,2,4-triazine-3,5-dione Chemical compound O=C1NC(=O)C=NN1C1=CC=CC=C1 XGPCOQNUQVZURR-UHFFFAOYSA-N 0.000 claims description 3
- WIDQEETVQZAVOK-UHFFFAOYSA-N 2-prop-2-ynyl-1,2,4-triazine-3,5-dione Chemical compound O=C1C=NN(CC#C)C(=O)N1 WIDQEETVQZAVOK-UHFFFAOYSA-N 0.000 claims description 3
- BMVMMPSJXUAHRL-UHFFFAOYSA-N 4-prop-2-ynyl-2h-1,2,4-triazine-3,5-dione Chemical compound O=C1C=NNC(=O)N1CC#C BMVMMPSJXUAHRL-UHFFFAOYSA-N 0.000 claims description 3
- BHUIUXNAPJIDOG-UHFFFAOYSA-N Piperonol Chemical compound OCC1=CC=C2OCOC2=C1 BHUIUXNAPJIDOG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical group CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- PRWATGACIORDEL-UHFFFAOYSA-N 2,4,5,6-tetra(carbazol-9-yl)benzene-1,3-dicarbonitrile Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=C(C#N)C(N2C3=CC=CC=C3C3=CC=CC=C32)=C(N2C3=CC=CC=C3C3=CC=CC=C32)C(N2C3=CC=CC=C3C3=CC=CC=C32)=C1C#N PRWATGACIORDEL-UHFFFAOYSA-N 0.000 claims description 2
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 claims description 2
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 2
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 claims description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 2
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- FNPNRZLYTIVLNO-UHFFFAOYSA-N Cl(=O)(=O)(=O)O.C1(=C(C(=CC(=C1)C)C)C1C2=CC=CC=C2N(C=2C=CC=CC12)C)C Chemical compound Cl(=O)(=O)(=O)O.C1(=C(C(=CC(=C1)C)C)C1C2=CC=CC=C2N(C=2C=CC=CC12)C)C FNPNRZLYTIVLNO-UHFFFAOYSA-N 0.000 claims description 2
- 229910020366 ClO 4 Inorganic materials 0.000 claims description 2
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 2
- 239000012425 OXONE® Substances 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 claims description 2
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 2
- 235000019395 ammonium persulphate Nutrition 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 2
- ZOAIGCHJWKDIPJ-UHFFFAOYSA-M caesium acetate Chemical compound [Cs+].CC([O-])=O ZOAIGCHJWKDIPJ-UHFFFAOYSA-M 0.000 claims description 2
- ZMCUDHNSHCRDBT-UHFFFAOYSA-M caesium bicarbonate Chemical compound [Cs+].OC([O-])=O ZMCUDHNSHCRDBT-UHFFFAOYSA-M 0.000 claims description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 150000002148 esters Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- DQDCGTUHSVXZIS-UHFFFAOYSA-N iodobenzene;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.IC1=CC=CC=C1 DQDCGTUHSVXZIS-UHFFFAOYSA-N 0.000 claims description 2
- UEEXRMUCXBPYOV-UHFFFAOYSA-N iridium;2-phenylpyridine Chemical compound [Ir].C1=CC=CC=C1C1=CC=CC=N1.C1=CC=CC=C1C1=CC=CC=N1.C1=CC=CC=C1C1=CC=CC=N1 UEEXRMUCXBPYOV-UHFFFAOYSA-N 0.000 claims description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 claims description 2
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 235000011056 potassium acetate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 claims description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 2
- 235000019394 potassium persulphate Nutrition 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- GJBRNHKUVLOCEB-UHFFFAOYSA-N tert-butyl benzenecarboperoxoate Chemical compound CC(C)(C)OOC(=O)C1=CC=CC=C1 GJBRNHKUVLOCEB-UHFFFAOYSA-N 0.000 claims description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 1
- 150000004292 cyclic ethers Chemical class 0.000 abstract description 8
- 238000005859 coupling reaction Methods 0.000 abstract description 5
- 238000006356 dehydrogenation reaction Methods 0.000 abstract description 5
- 239000003054 catalyst Substances 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 229910000510 noble metal Inorganic materials 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 63
- 125000001424 substituent group Chemical group 0.000 description 33
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 32
- 239000003208 petroleum Substances 0.000 description 32
- 239000000758 substrate Substances 0.000 description 32
- 238000004809 thin layer chromatography Methods 0.000 description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 31
- 239000005388 borosilicate glass Substances 0.000 description 31
- 239000012043 crude product Substances 0.000 description 31
- 239000001257 hydrogen Substances 0.000 description 31
- 229910052739 hydrogen Inorganic materials 0.000 description 31
- 239000000203 mixture Substances 0.000 description 31
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 24
- 239000012298 atmosphere Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006880 cross-coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002170 ethers Chemical group 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NCCXNCXTSSLEAP-UHFFFAOYSA-N 2,4-dimethyl-6-(oxolan-2-yl)-1,2,4-triazine-3,5-dione Chemical compound O=C1N(C)C(=O)N(C)N=C1C1OCCC1 NCCXNCXTSSLEAP-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FHGARXRHXDJXHV-UHFFFAOYSA-N C#CCN(C(C(C1OCCC1)=NN1)=O)C1=O Chemical compound C#CCN(C(C(C1OCCC1)=NN1)=O)C1=O FHGARXRHXDJXHV-UHFFFAOYSA-N 0.000 description 1
- BZOCDNJMGHDNNK-UHFFFAOYSA-N C#CCN(C(C(C1OCCC1)=NN1CC#C)=O)C1=O Chemical compound C#CCN(C(C(C1OCCC1)=NN1CC#C)=O)C1=O BZOCDNJMGHDNNK-UHFFFAOYSA-N 0.000 description 1
- BJVPJMCBIABJPW-UHFFFAOYSA-N C#CCN(C(N1)=O)N=C(C2OCCC2)C1=O Chemical compound C#CCN(C(N1)=O)N=C(C2OCCC2)C1=O BJVPJMCBIABJPW-UHFFFAOYSA-N 0.000 description 1
- DLLLOHYEOBODGY-UHFFFAOYSA-N CC(C)(C)OCC(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O Chemical compound CC(C)(C)OCC(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O DLLLOHYEOBODGY-UHFFFAOYSA-N 0.000 description 1
- KENOLNCLPRHWCU-UHFFFAOYSA-N CCCCOC(CCC)C(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O Chemical compound CCCCOC(CCC)C(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O KENOLNCLPRHWCU-UHFFFAOYSA-N 0.000 description 1
- ABTPYIDCTVYGHY-UHFFFAOYSA-N CCOC(C)C(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O Chemical compound CCOC(C)C(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O ABTPYIDCTVYGHY-UHFFFAOYSA-N 0.000 description 1
- ZRENFTZDZRGTCY-UHFFFAOYSA-N COC1(CCCC1)C(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O Chemical compound COC1(CCCC1)C(C(N1CC2=CC=CC=C2)=O)=NN(CC2=CC=CC=C2)C1=O ZRENFTZDZRGTCY-UHFFFAOYSA-N 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- CGXWYMSRIGDOAU-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1C(C=C2)=CC=C2Br)NC1=O Chemical compound O=C(C(C1OCCC1)=NN1C(C=C2)=CC=C2Br)NC1=O CGXWYMSRIGDOAU-UHFFFAOYSA-N 0.000 description 1
- JJHVHUAGXGTMPL-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1C(C=C2)=CC=C2F)NC1=O Chemical compound O=C(C(C1OCCC1)=NN1C(C=C2)=CC=C2F)NC1=O JJHVHUAGXGTMPL-UHFFFAOYSA-N 0.000 description 1
- BKUKRARPEZTSKZ-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1C2=CC=CC=C2)NC1=O Chemical compound O=C(C(C1OCCC1)=NN1C2=CC=CC=C2)NC1=O BKUKRARPEZTSKZ-UHFFFAOYSA-N 0.000 description 1
- HIDMZMARZLXXSF-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1CC(C=C2)=CC=C2Cl)N(CC(C=C2)=CC=C2Cl)C1=O Chemical compound O=C(C(C1OCCC1)=NN1CC(C=C2)=CC=C2Cl)N(CC(C=C2)=CC=C2Cl)C1=O HIDMZMARZLXXSF-UHFFFAOYSA-N 0.000 description 1
- XADCAIFGQLQZGT-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1CC(C=C2)=CC=C2F)N(CC(C=C2)=CC=C2F)C1=O Chemical compound O=C(C(C1OCCC1)=NN1CC(C=C2)=CC=C2F)N(CC(C=C2)=CC=C2F)C1=O XADCAIFGQLQZGT-UHFFFAOYSA-N 0.000 description 1
- ZDLQYMDWPXKMSV-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1CC(C=C2)=CC=C2F)NC1=O Chemical compound O=C(C(C1OCCC1)=NN1CC(C=C2)=CC=C2F)NC1=O ZDLQYMDWPXKMSV-UHFFFAOYSA-N 0.000 description 1
- JJGRBEJVPOGJGI-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound O=C(C(C1OCCC1)=NN1CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O JJGRBEJVPOGJGI-UHFFFAOYSA-N 0.000 description 1
- VCBPOOXSGXKIED-UHFFFAOYSA-N O=C(C(C1OCCC1)=NN1CC2=CC=CC=C2)NC1=O Chemical compound O=C(C(C1OCCC1)=NN1CC2=CC=CC=C2)NC1=O VCBPOOXSGXKIED-UHFFFAOYSA-N 0.000 description 1
- JYGSJYJTFSTKLD-UHFFFAOYSA-N O=C(C(C1OCCCC1)=NN1CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O Chemical compound O=C(C(C1OCCCC1)=NN1CC2=CC=CC=C2)N(CC2=CC=CC=C2)C1=O JYGSJYJTFSTKLD-UHFFFAOYSA-N 0.000 description 1
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明为一种6‑氧烷基1,2,4‑三嗪‑3,5(2H,4H)‑二酮类衍生物的制备方法。该方法以1,2,4‑三嗪‑3,5(2H,4H)‑二酮类化合物为原料直接与环醚或链醚发生交叉脱氢偶联反应,以可见光为光源,以有机光敏分子为光催化剂,避免使用贵金属催化剂,利用空气中的氧分子为绿色的氧化剂,无需额外添加氧化剂。本发明使用的试剂价格低廉,反应条件温和,后处理简单,适用于工业生产。
Description
技术领域
本发明涉及一类氧化的交叉脱氢偶反应,该反应可应用于制备具有药用前景的6号位氧烷基取代的1,2,4-三嗪-3,5(2H,4H)-二酮骨架结构分子,具体为一种6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法。
背景技术
1,2,4-三嗪-3,5(2H,4H)-二酮,又名6-氮杂尿嘧啶,即尿嘧啶6号位碳原子被氮原子代的化合物,是尿嘧啶的一种重要的衍生物。1,2,4-三嗪-3,5-二酮衍生物具有特殊的生理和药理活性。此外环醚结构也广泛出现于药物分子之中,将两者结合将有可能创造出新颖而具有特殊功效的药物分子。例如2020年,加拿大渥太华大学Pezacki课题组设计的双功能抑制剂Azauracil-AZT具有可高效的抑制HIV-1逆转录酶活性,有作为抗癌药的潜力。
6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物代表药物分子
现有的合成6位环醚取代的1,2,4-三嗪-3,5(2H,4H)-二酮类化合物方法主要有两种,如以下反应式所示:
现有方法一:环化反应
现有方法二:溴代-交叉偶联反应
现有的合成6位环醚取代的1,2,4-三嗪-3,5(2H,4H)-二酮方法
两种方法中,一种是酰肼类化物与伯胺通过环化反应合成,但该方法反应条件苛刻,所需的原料结构复杂不易制备,需要高温及微波的辅助,并且产率较低。另种是1,2,4-三嗪-3,5(2H,4H)-二酮类化物先发生卤代反应得到6位卤代1,2,4-三嗪-3,5(2H,4H)-二酮,卤代物再与四氢呋喃通过交叉偶联反应合成6位环醚取代的1,2,4-三嗪-3,5(2H,4H)-二酮类化合物,该方法合成路线较长需要预先引入卤素原子,再以卤素原子为反应位点引入环醚骨架,步骤和原子经济性差,并且该方法需要以昂贵的钯配合物为催化剂,在较高的温度下反应。由于缺乏简单高效的制备6位环醚取代的1,2,4-三嗪-3,5(2H,4H)-二酮或更复杂的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的方法,此类骨架药物分子的合成制备和药物活性研究受到限制。因此很有必要探索简单方便,绿色环保地合成6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的新方法。
发明内容
本发明的目的为针对当前技术中存在的不足,提供一种6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法。该方法以1,2,4-三嗪-3,5(2H,4H)-二酮类化合物为原料直接与环醚或链醚发生交叉脱氢偶联反应,在1,2,4-三嗪-3,5(2H,4H)-二酮类化合物的3号位直接引入氧烷基避免引入卤素原子的步骤,缩短合成线路,且副产物为水分子,具有优良的步骤和原子经济性。本反应以可见光为光源,以有机光敏分子为光催化剂,避免使用贵金属催化剂,利用空气中的氧分子为绿色的氧化剂,无需额外添加氧化剂。总之,本发明使用的试剂价格低廉,反应条件温和,后处理简单,适用于工业生产。
本发明的技术方案为:
一种6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,该方法包括如下步骤:
将1,2,4-三嗪-3,5(2H,4H)-二酮类化合物、光催化剂、氧化剂、碱加入到溶剂中,在可见光辐射下,于0-75摄氏度反应2-18小时,经柱层析分离提纯,最后得到6位氧烷基取代的1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物;
其中,摩尔比为1,2,4-三嗪-3,5(2H,4H)-二酮类化合物:光催化剂:氧化剂:碱=1:0.001-0.2:1.5-5:0.00-5(优选为0.01-5);溶剂用量为每毫摩尔的1,2,4-三嗪-3,5(2H,4H)-二酮类化合物使用2-15毫升溶剂;当物料的含量为0时,意味着没有添加该物质;当溶剂不是醚类化合物时,还需要加入醚类化合物,摩尔比为1,2,4-三嗪-3,5(2H,4H)-二酮类化合物:醚类化物=1:1.5-20;当以空气为氧化剂时,反应在开放条件下进行;
所述的可见光具体为LED蓝光(λmax=438nm;1W-30W)、LED白光(λ=380nm-760nm;1W–30W)或日光。
所述的1,2,4-三嗪-3,5(2H,4H)-二酮类化合物为:
其中,R1和R2相同或不同,分别为氢原子、甲基、乙基、烯丙基、炔丙基、乙酸乙酯、乙酸叔丁基酯、苯乙酮基、(2-(三甲基硅基)乙氧基)甲基、呋喃核糖基,脱氧呋喃核糖基、苯基、苄基以及甲基,氟原子、氯原子、溴原子、三氟甲基、氰基、甲酰基乙酯、硝基或甲氧基取代的芳基和苄基;
具体为N2,N4-二苄基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氟苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氯苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氰苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-甲氧基苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-二甲基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-二烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-二炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(乙酸乙酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(乙酸叔丁酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(乙酸叔丁酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氟苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氯苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-甲氧基苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-苯基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-(4-氟苯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-(4-溴苯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-苄基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-4-氟苄基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N4-烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N4-炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-(O3′,O5′-双对甲基苯甲酰基-2′-脱氧核糖基)-N4-甲基-1,2,4-三嗪-3,5(2H,4H)-二酮或N2-(O2′,O3′,O5′-三对甲基苯甲酰基核糖基)-N4-甲基-1,2,4-三嗪-3,5(2H,4H)-二酮;
所述的光催化剂为孟加拉玫瑰红(Rose Bengal)、曙红B(Eosin B)、曙红Y(EosinY)、罗丹明B(Rhodamine B)、10-甲基-9-均三甲苯基吖啶高氯酸盐(Acr+-Mes ClO4 -)、亚甲基蓝(Methylene blue)、吖啶红(Acridine red)、荧光素(Fluorescein)、三(2-苯基吡啶)合铱(fac-Ir(ppy)3)、(4,4'-二叔丁基-2,2'-联吡啶)双[(2-吡啶基)苯基]铱(III)六氟磷酸盐(Ir(ppy)2(dtbbpy)PF6)、三(2,2'-联吡啶)钌二(六氟磷酸)盐(Ru(bpy)3(PF6)2)、2,4,5,6-四(9-咔唑基)-间苯二腈或2-叔丁基蒽醌(2-t-Bu-AQN)。
所述的醚类化合物为四氢呋喃、1,4-二氧六环、四氢吡喃、1,3-二氧环戊烷、乙醚、二丁基醚、甲基叔丁基醚、甲基环戊基醚、1,2-二甲氧基乙烷、3,4-(亚甲二氧基)苯甲醇。
所述的氧化剂为:双三氟乙酸碘苯、双乙酸碘苯、叔丁基过氧化氢、过氧化氢异丙苯、过氧化苯甲酸叔丁酯、过氧化二叔丁基、过氧化二异丙苯、过氧苯甲酰、过氧乙酸、间氯过氧苯甲酸、双氧水、过二硫酸钾、过二硫酸钠,过二硫酸铵、过一硫酸氢钾复合盐、氧气或空气;
所述碱为碳酸铯、碳酸钾、碳酸钠、碳酸锂、氢氧化铯、氢氧化钾、氢氧化钠、氢氧化锂、醋酸铯、醋酸钾、醋酸钠、醋酸锂、磷酸钾、磷酸氢二钾,磷酸二氢钾,碳酸氢铯、碳酸氢钾、碳酸氢钠、碳酸氢锂、三乙胺、二乙基胺、正丁胺、吡啶、吗啉、吡咯烷、哌啶、哌嗪、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯、1,4-二氮杂二环[2.2.2]辛烷。
所述的溶剂为乙腈、丙腈、二氯甲烷、1,2-二氯乙烷、乙酸乙酯、丙酮、甲苯、三氟甲苯、甲醇、乙醇、异丙醇、四氢呋喃、1,4-二氧六环、四氢吡喃、1,3-二氧环戊烷、乙醚、二丁基醚、甲基叔丁基醚、甲基环戊基醚、1,2-二甲氧基乙烷、N,N-二甲基甲酰胺或二甲亚砜。
本发明的有益效果为:
1,2,4-三嗪-3,5(2H,4H)-二酮类化合物与醚类化合物发生氧化交叉脱氢偶联反应,在1,2,4-三嗪-3,5(2H,4H)-二酮类化合物6号位直接引入氧烷基,生产副产物为水分子,具有较高的原子和步骤经济性。该反应以2-t-Bu-AQN为光催化剂,避免使用贵金属催化剂;多种可见光源,甚至太阳光也可以驱动反应进行,体现出环保可持续的优势;以空气为绿色氧化剂,无需额外加入氧化剂;反应条件为温和,官能团兼容性好,芳基、苄基、烯丙基、炔丙基和烷氧羰基甲基等取代基取代的1,2,4-三嗪-3,5(2H,4H)-二酮以及多种环醚或链醚都适用于本方法。
具体实施方式
本发明以可见光为光源,在室温条件下,以空气中的氧分子为氧化剂,在光催化剂和碱的促进下,以醚类化合物为氧烷基源,在1,2,4-三嗪-3,5(2H,4H)-二酮类化合物的3号位直接引入氧烷基。本发明使用的试剂价格低廉,反应条件温和,后处理简单,适用于工业生产(如下反应式所示)。
氧化的交叉脱氢偶联反应合成6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物
下面结合具体实例,对本发明的方法进一步说明,但并不因此将本发明限制在所述的实例范围之中。下面实例中未注明具体条件的实验方法,按照常规的方法和条件,或按照商品说明书选择。
实施例1:15毫升的反应管中加入底物N2,N4-二苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基,2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌(此时反应敞口,空气流通,视为氧气过量)。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-二苄基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮100.9毫克,总收率92%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.47-7.45(m,2H),7.39-7.37(m,2H),7.34-7.23(m,6H),5.17-5.14(m,1H),5.05-5.00(m,4H),4.00-3.95(m,1H),3.92-3.87(m,1H),2.19-2.10(m,2H),2.02-1.91(m,2H),与结构式相符合。
实施例2:15毫升的反应管中加入底物N2,N4-双(4-氟苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮(98.7毫克,0.3毫摩尔,结构式上的取代基R1,R2为4-氟苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(4-氟苄基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮102.6毫克,总收率86%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.48-7.45(m,2H),7.39-7.36(m,2H),7.04-6.96(m,4H),5.14-5.10(m,1H),5.05-4.98(m,4H),4.01-3.96(m,1H),3.94-3.89(m,1H),2.21-2.10(m,2H),2.09-1.93(m,2H),与结构式相符合。
实施例3:15毫升的反应管中加入底物N2,N4-双(4-氯苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮(108.3毫克,0.3毫摩尔,结构式上的取代基R1,R2为4-氯苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(4-氯苄基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮100.6毫克,总收率78%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.41(d,J=8Hz,2H),7.31(s,4H),7.27(d,J=8Hz,2H),5.13-5.09(m,1H),5.04-4.98(m,4H),4.01-3.95(m,1H),3.94-3.88(m,1H),2.21-2.09(m,2H),2.04-1.95(m,2H),与结构式相符合。
实施例4:15毫升的反应管中加入底物N2,N4-双(4-氰苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮(102.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为4-氰苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(4-氰苄基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮103.5毫克,总收率84%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.64(d,J=8Hz,2H),7.60-7.54(m,4H),7.48(d,J=8Hz,2H),5.21-5.09(m,4H),5.04-5.00(m,1H),4.01-3.95(m,1H),3.95-3.89(m,1H),2.26-2.09(m,2H),2.04-1.98(m,2H),与结构式相符合。
实施例5:15毫升的反应管中加入底物N2,N4-双(4-甲氧基苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮(105.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为4-甲氧基苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(4-甲氧基苄基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮109.0毫克,总收率86%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.43(d,J=8Hz,2H),7.33(d,J=8Hz,2H),6.86-6.81(m,4H),5.11-4.99(m,4H),4.97-4.94(m,1H),4.01-3.96(m,1H),3.93-3.88(m,1H),3.78(s,3H),3.76(s,3H),2.18-2.10(m,2H),2.03-1.93(m,2H),与结构式相符合。
实施例6:15毫升的反应管中加入底物N2,N4-二甲基-1,2,4-三嗪-3,5(2H,4H)-二酮(42.3毫克,0.3毫摩尔,结构式上的取代基R1,R2为甲基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-二甲基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮49.8毫克,总收率78%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ5.02-4.99(m,1H),4.06-4.00(m,1H),3.94-3.90(m,1H),3.63(s,3H),3.34(s,3H),2.26-2.21(m,1H),2.13-1.98(m,3H),与结构式相符合。
实施例7:15毫升的反应管中加入底物N2,N4-二烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮(57.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为烯丙基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-二烯丙基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮65.2毫克,总收率82%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ5.98-5.80(m,2H),5.32-5.21(m,4H),5.04-5.00(m,1H),4.62-4.52(m,4H),4.04-3.98(m,1H),3.94-3.90(m,1H),2.25-2.10(m,2H),2.08-1.94(m,2H),与结构式相符合。
实施例8:15毫升的反应管中加入底物N2,N4-二炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮(56.7毫克,0.3毫摩尔,结构式上的取代基R1,R2为炔丙基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-二炔丙基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮64.7毫克,总收率83%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ5.07-5.03(m,1H),4.83-4.69(m,4H),4.07-4.02(m,1H),3.96-3.91(m,1H),2.38-2.37(m,1H),2.28-2.16(m,3H),2.12-2.06(m,1H),2.04-1.97(m,1H),与结构式相符合。
实施例9:15毫升的反应管中加入底物N2,N4-双(乙酸乙酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮(85.5毫克,0.3毫摩尔,结构式上的取代基R1,R2为乙酸乙酯基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(乙酸乙酯基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮66.1毫克,总收率62%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ5.04-5.01(m,1H),4.76-4.64(m,4H),4.25-4.19(m,4H),4.03-3.97(m,1H),3.93-3.88(m,1H),2.29-2.21(m,1H),2.15-2.06(m,1H),2.04-1.95(m,2H),1.29-1.25(m,6H),与结构式相符合。
实施例10:15毫升的反应管中加入底物N2,N4-双(乙酸叔丁酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮(102.3毫克,0.3毫摩尔,结构式上的取代基R1,R2为乙酸叔丁酯基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(乙酸叔丁酯基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮96.7毫克,总收率78%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ5.06-5.03(m,1H),4.67-4.56(m,4H),4.04-3.98(m,1H),3.94-3.89(m,1H),2.30-2.22(m,1H),2.15-2.09(m,1H),2.06-1.95(m,2H),1.47(s,9H),1.46(s,9H),与结构式相符合。
实施例11:15毫升的反应管中加入底物N2,N4-双(苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮(104.7毫克,0.3毫摩尔,结构式上的取代基R1,R2为苯乙酮基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(苯乙酮基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮102.8毫克,总收率82%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ8.00-7.96(m 4H),7.65-7.60(m,2H),7.53-7.48(m,4H),5.51-5.39(m,4H),5.09-5.06(m,1H),4.03-3.98(m,1H),3.93-3.88(m,1H),2.32-2.23(m,1H),2.19-2.10(m,1H),2.06-1.93(m,2H),与结构式相符合。
实施例12:15毫升的反应管中加入底物N2,N4-双(4-氟苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮(115.5毫克,0.3毫摩尔,结构式上的取代基R1,R2为4-氟苯乙酮基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(4-氟苯乙酮基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮107.2毫克,总收率78%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ8.03-7.97(m,4H),7.19-7.14(m,4H),5.46-5.34(m,4H),5.06-5.03(m,1H),4.01-3.96(m,1H),3.92-3.87(m,1H),2.30-2.22(m,1H),2.16-2.08(m,1H),2.05-1.92(m,2H),与结构式相符合。
实施例13:15毫升的反应管中加入底物N2,N4-双(4-氯苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮(125.1毫克,0.3毫摩尔,结构式上的取代基R1,R2为4-氯苯乙酮基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(4-氯苯乙酮基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮107.5毫克,总收率73%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.93-7.88(m,4H),7.48-7.46(m,4H),5.45-5.33(m,4H),5.06-5.03(m,1H),4.02-3.96(m,1H),3.92-3.87(m,1H),2.31-2.22(m,1H),2.16-2.08(m,1H),2.03-1.94(m,2H),与结构式相符合。
实施例14:15毫升的反应管中加入底物N2,N4-双(4-甲氧基苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮(122.7毫克,0.3毫摩尔,结构式上的取代基R1,R2为4-甲氧基苯乙酮基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双(4-甲氧基苯乙酮基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮104.5毫克,总收率73%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.95-7.91(m,4H),6.95-6.92(m,4H),5.44-5.32(m,4H),5.06-5.03(m,1H),4.01-3.95(m,1H),3.90-3.87(m,1H),3.85(s,6H),2.26-2.20(m,1H),2.16-2.08(m,1H),2.03-1.92(m,2H),与结构式相符合。
实施例15:15毫升的反应管中加入底物N2-苯基-1,2,4-三嗪-3,5(2H,4H)-二酮(56.7毫克,0.3毫摩尔,结构式上的取代基R1为苯基,R2为氢原子),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-苯基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮70.2毫克,总收率90%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ10.30(s,1H),7.53-7.45(m,3H),7.25(d,J=8Hz,2H),5.06-5.03(m,1H),4.11-4.05(m,1H),3.97-3.91(m,1H),2.36-2.27(m,1H),2.14-2.00(m,3H),与结构式相符合。
实施示例16:15毫升的反应管中加入底物N2-(4-氟苯基)-1,2,4-三嗪-3,5(2H,4H)-二酮(62.1毫克,0.3毫摩尔,结构式上的取代基R1为4-氟苯基,R2为氢原子),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-(4-氟苯基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮56.7毫克,总收率68%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ9.92(s,1H),7.25-7.22(m,2H),7.20-7.17(m,2H),5.06-5.02(m,1H),4.10-4.04(m,1H),3.97-3.92(m,1H),2.34-2.29(m,1H),2.13-2.01(m,3H),与结构式相符合。
实施例17:15毫升的反应管中加入底物N2-(4-溴苯基)-1,2,4-三嗪-3,5(2H,4H)-二酮(80.1毫克,0.3毫摩尔,结构式上的取代基R1为4-溴苯基,R2为氢原子),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-(4-溴苯基)-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮76.0毫克,总收率75%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ10.25(s,1H),7.63(d,J=8Hz,2H),7.13(d,J=8Hz,2H),5.05-5.02(m,1H),4.09-4.04(m,1H),3.97-3.91(m,1H),2.35-2.26(m,1H),2.12-1.99(m,3H),与结构式相符合。
实施例18:15毫升的反应管中加入底物N2-苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(60.9毫克,0.3毫摩尔,结构式上的取代基R1为苄基,R2为氢原子),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-苄基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮54.9毫克,总收率67%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ10.3(s,1H),7.49-7.47(m,2H),7.33-7.28(m,3H),5.07(s,2H),5.04-5.00(m,1H),4.07-4.02(m,1H),3.94-3.89(m,1H),2.33-2.27(m,1H),2.08-1.97(m,3H),与结构式相符合。
实施例19:15毫升的反应管中加入底物N2-4-氟苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(66.36毫克,0.3毫摩尔,结构式上的取代基R1为4-氟苄基,R2为氢原子),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-4-氟苄基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮55.0毫克,总收率63%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ10.2(s,1H),7.50-7.47(m,2H),7.02-6.97(m,2H),5.03(s,2H),5.02-5.00(m,1H),4.07-4.02(m,1H),3.95-3.90(m,1H),2.34-2.26(m,1H),2.08-1.96(m,3H),与结构式相符合。
实施例20:15毫升的反应管中加入底物N2-烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮(45.92毫克,0.3毫摩尔,结构式上的取代基R1为烯丙基,R2为氢原子),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-烯丙基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮24.2毫克,总收率55%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ9.57(s,1H),5.92-5.82(m,1H),5.34-5.24(m,2H),5.05-5.01(m,1H),4.52(d,J=4Hz,2H),4.07-4.02(m,1H),3.96-3.91(m,1H),2.34-2.27(m,1H),2.11-1.99(m,3H),与结构式相符合。
实施例21:15毫升的反应管中加入底物N2-炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮(45.3毫克,0.3毫摩尔,结构式上的取代基R1为炔丙基,R2为氢原子),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-炔丙基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮39.6毫克,总收率60%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ10.39(s,1H),5.04(t,J=8Hz,1H),4.68-4.68(m,2H),4.10-4.05(m,1H),3.97-3.92(m,1H),2.37-2.30(m,1H),2.24-2.23(m,1H),2.12-2.01(m,3H),与结构式相符合。
实施例22:15毫升的反应管中加入底物N4-烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮(45.9毫克,0.3毫摩尔,结构式上的取代基R1为氢原子,R2为烯丙基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N4-烯丙基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮34.8毫克,总收率52%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ9.50(s,1H),5.97-5.87(m,1H),5.31-5.26(m,2H),5.02(t,J=8Hz,1H),4.62-4.49(m,2H),4.05-3.99(m,1H),3.96-3.90(m,1H),2.24-2.14(m,2H),2.08-1.98(m,2H),与结构式相符合。
实施例23:15毫升的反应管中加入底物N2-(O3′,O5′-双对甲基苯甲酰基-2′-脱氧核糖基)-N4-甲基-1,2,4-三嗪-3,5(2H,4H)-二酮(143.8毫克,0.3毫摩尔,结构式上的取代基R1为O3′,O5′-双对甲基苯甲酰基-2′-脱氧核糖基,R2为甲基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2-(O3′,O5′-双对甲基苯甲酰基-2′-脱氧核糖基)-N4-甲基--6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮125.2毫克,总收率76%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.95-7.89(m,4H),7.26-7.18(m,4H),6.76-6.72(m,1H),5.75-5.71(m,1H),5.09-5.05(m,1H),4.56-4.47(m,3H),4.07-4.01(m,1H),3.96-3.91(m,1H),3.35(s,3H),2.53-2.47(m,1H),2.43(s,3H),2.39(s,3H),2.25-2.13(m,2H),2.08-1.98(m,2H),与结构式相符合。
实施例24:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升1,4-二氧六环用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(2-(1,4-二氧六环)基)-1,2,4-三嗪-3,5(2H,4H)-二酮103.4毫克,总收率91%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.47-7.45(m,2H),7.39-7.29(m,8H),5.22-5.03(m,4H),4.87-4.83(m,1H),3.93-3.84(m,3H),3.79-3.85(m,3H),与结构式相符合。
实施例25:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢吡喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(2-四氢吡喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮100.4毫克,总收率89%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.46-7.44(m,2H),7.40-7.38(m,2H),7.35-7.27(m,6H),5.23-5.03(m,4H),4.62-4.58(m,1H),4.13-4.09(m,1H),3.63-3.57(m,1H),1.96-1.93(m,1H),1.81-1.70(m,3H),1.68-1.55(m,3H),与结构式相符合。
实施例26:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升乙醚用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(1-乙氧基乙基)-1,2,4-三嗪-3,5(2H,4H)-二酮79.4毫克,总收率72%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.48-7.47(m,2H),7.42-7.37(m,2H),7.34-7.29(m,6H),5.16-5.07(m,4H),4.67(q,J=8Hz),3.52(q,J=8Hz),1.44(d,J=8Hz),1.19(t,J=8Hz),与结构式相符合。
实施例27:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升丁醚用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(1-丁氧基丁基)-1,2,4-三嗪-3,5(2H,4H)-二酮105.0毫克,总收率83%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.48-7.45(m,2H),7.41-7.39(m,2H),7.32-7.27(m,6H),5.17-5.07(m,4H),4.50-4.47(m,1H),3.48-3.42(m,1H),3.38-3.32(m,1H),1.79-1.73(m,2H),1.56-1.46(m,3H),1.39-1.28(m,3H),0.92(t,J=8Hz),0.87(t,J=8Hz),与结构式相符合。
实施例28:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升甲基叔丁基醚用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(叔丁氧甲基)-1,2,4-三嗪-3,5(2H,4H)-二酮82.7毫克,总收率73%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.47-7.45(m,2H),7.40-7.39(m,2H),7.34-7.27(m,6H),5.10(s,2H),5.07(s,2H),4.33(s,2H),1.26(s,9H),与结构式相符合。
实施例29:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升甲基环戊基醚用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(1-甲氧基环戊基)-1,2,4-三嗪-3,5(2H,4H)-二酮70.4毫克,总收率60%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.48(d,J=8Hz,2H),7.39(d,J=8Hz,2H),7.34-7.29(m,2H),5.10(s,2H),5.08(s,2H),3.04(s,3H),2.22-2.16(m,2H),2.03-1.95(m,2H),1.79-1.75(m,2H),1.66-1.60(m,2H),与结构式相符合。
实施例30:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升1,3-二氧杂环戊烷用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(2-(1,3-氧代环戊)基)-1,2,4-三嗪-3,5(2H,4H)-二酮68.1毫克,总收率62%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.45(d,J=8Hz,2H),7.38-7.26(m,8H),5.89(s,1H),5.09(s,2H),5.05(s,2H),4.20-4.17(m,2H),4.02-3.99(m,2H),与结构式相符合。
实施例31:15毫升的反应管中加入底物N4-炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮(45.3毫克,0.3毫摩尔,结构式上的取代基R1为氢原子,R2为炔丙基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔)和磁子,将2毫升四氢呋喃用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余四氢呋喃,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N4-炔丙基-6-(2-四氢呋喃基)-1,2,4-三嗪-3,5(2H,4H)-二酮36.1毫克,总收率54%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ9.35(s,1H),5.04(t,J=8Hz,1H),4.79-4.67(m,2H),4.08-4.02(m,1H),3.97-3.91(m,1H),2.35(s,1H),2.28-2.16(m,2H),2.10-1.98(m,2H),与结构式相符合。
实施例32:15毫升的反应管中加入底物N2,N4-双苄基-1,2,4-三嗪-3,5(2H,4H)-二酮(87.9毫克,0.3毫摩尔,结构式上的取代基R1,R2为苄基),2-叔丁基蒽醌(2.4毫克,0.009毫摩尔),碳酸铯(48.9毫克,0.15毫摩尔),3,4-(亚甲二氧基)苯甲醇(456.4毫克,3.0毫摩尔)和磁子,将2毫升乙酸乙酯用注射器加入。将此混合在LED蓝光(λmax=438nm,25W,光源距反应管4cm,反应管为普通硼硅酸玻璃材质)的辐射下,室温敞口在空气环境下搅拌。薄层色谱检测反应基本完全或不再转化,停止反应,减压蒸馏除去多余溶剂,得粗产物直接用柱层析分离(乙酸乙酯/石油醚=1/3)得到产物N2,N4-双苄基-6-(2-(5-羟甲基)苯并[d][1,3]二氧环戊基)-1,2,4-三嗪-3,5(2H,4H)-二酮52.9毫克,总收率40%。
所得产品的氢原子核磁共振谱数据为1H NMR(400MHz,CDCl3)δ7.43(d,J=8Hz,2H),7.29(d,J=8Hz,2H),7.25(s,1H),6.94(s,1H),6.89(s,1H),6.85(d,J=8Hz,1H),6.80(d,J=8Hz,1H),5.08(s,2H),5.03(s,2H),4.59(s,2H),与结构式相符合。
本发明未尽事宜为公知技术。
Claims (9)
1.一种6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,该方法包括如下步骤:
将1,2,4-三嗪-3,5(2H,4H)-二酮类化合物、光催化剂、氧化剂、碱加入到溶剂中,在可见光辐射下,于0-75摄氏度反应2-18小时,经柱层析分离提纯,最后得到6位氧烷基取代的1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物;
其中,摩尔比为1,2,4-三嗪-3,5(2H,4H)-二酮类化合物:光催化剂:醚类化物:氧化剂:碱=1:0.001-0.2:1.5-5:0.00-5(优选为0.01-5);溶剂用量为每毫摩尔的1,2,4-三嗪-3,5(2H,4H)-二酮类化合物使用2-15毫升溶剂;当物料的含量为0时,意味着没有添加该物质;当溶剂不是醚类化合物时,还需要加入醚类化合物,摩尔比为1,2,4-三嗪-3,5(2H,4H)-二酮类化合物:醚类化物=1:1.5-20。
2.如权利要求1所述的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,其特征为所述的可见光具体为LED蓝光(λmax=438nm;1W-30W)、LED白光(λ=380nm-760nm;1W–30W)或日光。
4.如权利要求1所述的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,其特征为具体为N2,N4-二苄基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氟苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氯苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氰苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-甲氧基苄基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-二甲基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-二烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-二炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(乙酸乙酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(乙酸叔丁酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(乙酸叔丁酯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氟苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-氯苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2,N4-双(4-甲氧基苯乙酮基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-苯基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-(4-氟苯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-(4-溴苯基)-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-苄基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-4-氟苄基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N4-烯丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N4-炔丙基-1,2,4-三嗪-3,5(2H,4H)-二酮、N2-(O3′,O5′-双对甲基苯甲酰基-2′-脱氧核糖基)-N4-甲基-1,2,4-三嗪-3,5(2H,4H)-二酮或N2-(O2′,O3′,O5′-三对甲基苯甲酰基核糖基)-N4-甲基-1,2,4-三嗪-3,5(2H,4H)-二酮。
5.如权利要求1所述的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,其特征为所述的光催化剂为孟加拉玫瑰红(Rose Bengal)、曙红B(Eosin B)、曙红Y(EosinY)、罗丹明B(Rhodamine B)、10-甲基-9-均三甲苯基吖啶高氯酸盐(Acr+-Mes ClO4 -)、亚甲基蓝(Methylene blue)、吖啶红(Acridine red)、荧光素(Fluorescein)、三(2-苯基吡啶)合铱(fac-Ir(ppy)3)、(4,4'-二叔丁基-2,2'-联吡啶)双[(2-吡啶基)苯基]铱(III)六氟磷酸盐(Ir(ppy)2(dtbbpy)PF6)、三(2,2'-联吡啶)钌二(六氟磷酸)盐(Ru(bpy)3(PF6)2)、2,4,5,6-四(9-咔唑基)-间苯二腈、2-叔丁基蒽醌(2-t-Bu-AQN)。
6.如权利要求1所述的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,其特征为所述的醚类化合物为四氢呋喃、1,4-二氧六环、四氢吡喃、1,3-二氧环戊烷、乙醚、二丁基醚、甲基叔丁基醚、甲基环戊基醚、1,2-二甲氧基乙烷、3,4-(亚甲二氧基)苯甲醇。
7.如权利要求1所述的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,其特征为所述的氧化剂为:双三氟乙酸碘苯、双乙酸碘苯、叔丁基过氧化氢、过氧化氢异丙苯、过氧化苯甲酸叔丁酯、过氧化二叔丁基、过氧化二异丙苯、过氧苯甲酰、过氧乙酸、间氯过氧苯甲酸、双氧水、过二硫酸钾、过二硫酸钠,过二硫酸铵、过一硫酸氢钾复合盐、氧气或空气;当以空气为氧化剂时,反应在开放条件下进行。
8.如权利要求1所述的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,其特征为所述碱为碳酸铯、碳酸钾、碳酸钠、碳酸锂、氢氧化铯、氢氧化钾、氢氧化钠、氢氧化锂、醋酸铯、醋酸钾、醋酸钠、醋酸锂、磷酸钾、磷酸氢二钾,磷酸二氢钾,碳酸氢铯、碳酸氢钾、碳酸氢钠、碳酸氢锂、三乙胺、二乙基胺、正丁胺、吡啶、吗啉、吡咯烷、哌啶、哌嗪、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯、1,4-二氮杂二环[2.2.2]辛烷。
9.如权利要求1所述的6-氧烷基1,2,4-三嗪-3,5(2H,4H)-二酮类衍生物的制备方法,其特征为所述的溶剂为乙腈、丙腈、二氯甲烷、1,2-二氯乙烷、乙酸乙酯、丙酮、甲苯、三氟甲苯、甲醇、乙醇、异丙醇、四氢呋喃、1,4-二氧六环、四氢吡喃、1,3-二氧环戊烷、乙醚、二丁基醚、甲基叔丁基醚、甲基环戊基醚、1,2-二甲氧基乙烷、N,N-二甲基甲酰胺或二甲亚砜。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210493704.1A CN115583919B (zh) | 2022-04-27 | 2022-04-27 | 一种6-氧烷基1,2,4-三嗪-3,5(2h,4h)-二酮类衍生物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210493704.1A CN115583919B (zh) | 2022-04-27 | 2022-04-27 | 一种6-氧烷基1,2,4-三嗪-3,5(2h,4h)-二酮类衍生物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115583919A true CN115583919A (zh) | 2023-01-10 |
CN115583919B CN115583919B (zh) | 2024-04-19 |
Family
ID=84771367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210493704.1A Active CN115583919B (zh) | 2022-04-27 | 2022-04-27 | 一种6-氧烷基1,2,4-三嗪-3,5(2h,4h)-二酮类衍生物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115583919B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1263526A (zh) * | 1997-08-29 | 2000-08-16 | 武田药品工业株式会社 | 三嗪衍生物,其制备及应用 |
CN103087049A (zh) * | 2011-11-03 | 2013-05-08 | 中国科学院大连化学物理研究所 | 2,6-二[(5,6-二烷基)-1,2,4-三嗪-3-基]-吡啶及其制备方法 |
CN103588718A (zh) * | 2006-11-10 | 2014-02-19 | 艾德斯药物股份有限公司 | 作为gabab受体调节剂的新三嗪二酮衍生物 |
CN108976174A (zh) * | 2018-07-06 | 2018-12-11 | 河北工业大学 | 一种3-三氟甲基喹喔啉酮类化合物制备方法 |
CN113278013A (zh) * | 2020-02-20 | 2021-08-20 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
-
2022
- 2022-04-27 CN CN202210493704.1A patent/CN115583919B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1263526A (zh) * | 1997-08-29 | 2000-08-16 | 武田药品工业株式会社 | 三嗪衍生物,其制备及应用 |
CN103588718A (zh) * | 2006-11-10 | 2014-02-19 | 艾德斯药物股份有限公司 | 作为gabab受体调节剂的新三嗪二酮衍生物 |
CN103087049A (zh) * | 2011-11-03 | 2013-05-08 | 中国科学院大连化学物理研究所 | 2,6-二[(5,6-二烷基)-1,2,4-三嗪-3-基]-吡啶及其制备方法 |
CN108976174A (zh) * | 2018-07-06 | 2018-12-11 | 河北工业大学 | 一种3-三氟甲基喹喔啉酮类化合物制备方法 |
CN113278013A (zh) * | 2020-02-20 | 2021-08-20 | 昆药集团股份有限公司 | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
HANNA WÓJTOWICZ-RAJCHEL等: "《Palladium-catalysed cross coupling of perfluoroalkenyl zinc reagents with 5-halo-6-azaurac》", MENDELEEV COMMUN, vol. 14, no. 2 * |
PRITHWISH GHOSH等: "《Reactivity of triplet diradical intermediates in aqueous media for transition-metal-free Csp2– H alkylation》", CELL REPORTS PHYSICAL SCIENCE 3, no. 100819 * |
TYLER A. SHAW等: "《A Bifunctional Nucleoside Probe for the Inhibition of the Human Immunodeficiency Virus-Type 1 Reverse Transcriptase》", BIOCONJUGATE CHEM, no. 31 * |
Also Published As
Publication number | Publication date |
---|---|
CN115583919B (zh) | 2024-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108752325B (zh) | 一种3-氧烷基喹喔啉-2(1h)-酮类化合物的制备方法 | |
Dinnocenzo et al. | Nucleophile-assisted cleavage of silane cation radicals | |
Kusy et al. | Microwave-assisted synthesis of 3-formyl substituted imidazo [1, 2-a] pyridines | |
US3709874A (en) | 1-beta-d-arabinofuranosyl cytosine derivatives and methods of preparing | |
Nishida et al. | Hydrolysis of tosyl esters initiated by an electron transfer from photoexcited electron-rich aromatic compounds | |
Shi et al. | Concise and divergent total synthesis of swainsonine, 7-alkyl swainsonines, and 2, 8a-diepilentiginosine via a chiral heterocyclic enaminoester intermediate | |
Buchi et al. | Total synthesis of tryptoquivaline G | |
CN112645958A (zh) | 一种手性螺环吡唑啉酮化合物及制备方法 | |
Kuehne et al. | Total syntheses of tubotaiwine and 19, 20-dihydro-20-epi-akuammicine | |
Casiraghi et al. | The four-carbon elongation of aldehydo sugars using 2-(trimethylsiloxy) furan: a butenolide route to higher monosaccharides | |
CN115583919B (zh) | 一种6-氧烷基1,2,4-三嗪-3,5(2h,4h)-二酮类衍生物的制备方法 | |
Somei et al. | The Chemistry of Indoles. XXXIII.: Substituent Effect in Regioselective Metalation of 3-Indolecarbaldehyde and Syntheses of Indoles Carrying a Carbon Side Chain at the 4-, 5-, 6-, or 7-Position | |
Beemelmanns et al. | Highly diastereoselective samarium diiodide induced ketyl cyclisations of indole and pyrrole derivatives–scope and limitations | |
Xu et al. | A radical addition and cyclization relay promoted by Mn (OAc) 3⋅ 2H2O: Synthesis of 1, 2-oxaphospholoindoles and mechanistic study | |
Ashton et al. | Synthesis of 8‐demethyl‐8‐hydroxy‐5‐deazariboflavins | |
Warren et al. | Uroporphyrinogen III methylase catalyzes the enzymic synthesis of sirohydrochlorins II and IV by a clockwise mechanism | |
Banwell et al. | cis-1, 2-dihydrocatechols in chemical synthesis: first synthesis of L-ascorbic acid (vitamin C) from a non-carbohydrate source | |
CN110156730B (zh) | 一种手性三环苯并呋喃类化合物的合成方法 | |
Yamamoto et al. | New regiocontrolled syntheses of pyrrolopyrazinones and its application to the synthesis of peramine | |
US8884005B2 (en) | Method for the preparation of carbapenam compounds | |
Pavlova et al. | Alkyl Orthoesters and Their Applications in Organic Synthesis | |
Zhu et al. | Reactions of fluoroalkanesulfonyl azides with cyclic vinyl ethers | |
Kimishima et al. | Single-step construction of an acetoxypyrroloindole skeleton via tandem iodocyclization/acetoxylation of indoles | |
Keith et al. | Pyrolysis and structure of jesaconitine | |
CN115353478B (zh) | 一种吲哚类化合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |